Treatment study for classical Hodgkin lymphoma in young people
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at a treatment approach for children and adolescents with classical Hodgkin lymphoma. It may help by testing how well the treatment controls the cancer and is tolerable in young patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with classical Hodgkin lymphoma (not lymphocyte-predominant type).
- You are under 18, or in some participating countries you may be eligible up to under 25 in special teen/young-adult units.
- You (and your parent/guardian, if required) can provide informed consent according to your local rules.
- If you could become pregnant, you need a negative pregnancy test within 2 weeks before starting treatment.
- You cannot have had chemotherapy or radiation for another cancer in the past.
- You must be able to follow the trial in a participating country and have no other active (simultaneous) cancers or recent trial study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
This trial studies a treatment plan for children with classical Hodgkin lymphoma that uses lower total doses of chemotherapy and reduced radiation. The goal is to help control the lymphoma while lowering long-term side effects.
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This study is for children with “classical” Hodgkin lymphoma to help guide the best treatment plan. It may help your care team choose therapy based on what has worked for similar children.
This trial studies the best first chemotherapy approach for people newly diagnosed with classical Hodgkin lymphoma. It may help improve outcomes by comparing how treatment is given in routine care settings in Russia.
Hear when a new Classical Hodgkins Lymphoma in Children and Adolescents. trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.